8-KEarnings & ResultsExhibits & Filings

Edwards Lifesciences Corp 8-K Report, Financial Results (Apr 23, 2013)

Filed April 23, 2013For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on April 23, 2013, primarily to report its financial results for the first quarter of 2013. The filing includes a press release, furnished as Exhibit 99.1, which details the company's performance during the period. Investors should review this press release for specific financial metrics, revenue figures, and any commentary on operational performance, as this 8-K serves as the official notification of these results. While the 8-K itself is a procedural document, the incorporated press release is the key informational component for shareholders. It would typically cover the company's earnings per share (EPS), net sales, and guidance for the upcoming periods, offering insights into the company's trajectory in the cardiovascular medical device sector. Investors are encouraged to examine the press release for year-over-year comparisons and any management outlook provided.

Key Highlights

  • 1Filing of an 8-K on April 23, 2013, by Edwards Lifesciences Corporation.
  • 2The primary purpose of the filing is to report Q1 2013 financial results.
  • 3A press release detailing the Q1 2013 financial results is attached as Exhibit 99.1.
  • 4The press release is incorporated by reference into the 8-K filing.
  • 5The filing indicates the company's performance was discussed on April 23, 2013.
  • 6The Chief Financial Officer, Thomas M. Abate, signed the report.
  • 7The report confirms the company is registered in Delaware and headquartered in Irvine, California.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce and provide Edwards Lifesciences Corporation's financial results for the first quarter of 2013. This is typically done through an accompanying press release.

The detailed financial results for the first quarter of 2013 are provided in the press release, which is included as Exhibit 99.1 to this 8-K filing and is incorporated by reference.

This specific 8-K filing itself is procedural and only announces the results. The accompanying press release (Exhibit 99.1) would contain the detailed financial performance and any forward-looking statements or guidance provided by the company for future periods.

The 8-K report was signed by Thomas M. Abate, Corporate Vice President and Chief Financial Officer of Edwards Lifesciences Corporation.